Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 8/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RHOA | P61586 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838008 | 0.86 | RHOA (0.59) | HDAC4HSD11B1L3MBTL1RHOASCD | |
| SCHEMBL2227588 | 0.80 | MEN1 (0.60) | HDAC4HDAC6HDAC8HDAC3HDAC7 | |
| SCHEMBL14645751 | 0.79 | HDAC4 (1.00) | HDAC4HDAC6HDAC8HDAC3HDAC7 | |
| SCHEMBL2224878 | 0.78 | HDAC4 (0.56) | HDAC4HDAC6HDAC8HDAC3HDAC7 | |
| SCHEMBL2227129 | 0.76 | HDAC4 (0.71) | HDAC4HDAC6HDAC8SCD | |
| SCHEMBL2226536 | 0.75 | HDAC4 (0.61) | HDAC4HDAC6HDAC8HDAC3HDAC7 | |
| SCHEMBL2228048 | 0.74 | GRM5 (0.50) | HDAC4HDAC6HSD11B1HDAC8HDAC7 | |
| SCHEMBL2225290 | 0.74 | GRM5 (0.54) | HDAC4HDAC6HSD11B1HDAC8L3MBTL1 | |
| SCHEMBL2223961 | 0.74 | HDAC4 (0.56) | HDAC4HDAC6HDAC8HDAC7HDAC9 | |
| SCHEMBL2225406 | 0.74 | HDAC4 (0.55) | HDAC4HDAC6HDAC8HDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013009827-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | claimed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2013009827-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| EP-2523664-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | HDAC4 2773/4885HDAC6 1763/4885HSD11B1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.